Odd. I thought they just finished enrolling their
Post# of 148182
"“The FDA did not agree to grant (emergency use authorisation), as applied for in September,” said Jonathan Javitt, the chief executive officer of U.S.-based NeuroRx"
I assume they are still awaiting results from their current severe/critical trial, so what was their basis for the EUA request back in September?
Should be an interesting day for them, to say the least.
(I have a little spec position, but don't follow it that closely)